Accuray Rolls Out PlanTouch for the CyberKnife System

SUNNYVALE, Calif., March 26, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today the release of PlanTouch™, the first commercially available, fully integrated software application in radiation oncology that allows physicians to remotely review and approve patients' radiation treatment plans on the iPad. The PlanTouch software, developed in partnership with MIM Software Inc., Cleveland, Ohio, frees physicians using the CyberKnife® Robotic Radiosurgery System from work stations and provides them with increased collaboration, mobility, flexibility and convenience in delivering high-quality patient care. PlanTouch has received 510(k) clearance from the U.S. Food & Drug Administration (FDA).

(Photo:  http://photos.prnewswire.com/prnh/20120326/SF73004)

PlanTouch's interface is fully integrated with the CyberKnife System's data management and planning software. Physicians can now review dose volume histograms, isodose curves, contours, and images and approve treatment plans directly from their iPads. This new mobile solution can enable improved collaboration between the radiation oncologist and referring physicians, such as thoracic surgeons, urologists and neurosurgeons. Physicians are no longer tied to planning workstations, but instead can access treatment plans remotely, wherever and whenever they need to, ensuring a seamless and efficient workflow. The ability not only to review, but also to approve a treatment plan is a function not available with any other tablet-based radiation oncology application on the market today.

"I am confident that PlanTouch will make our department more efficient by allowing us to speed up the time between consult, planning and initiation of treatment, which will, in turn, enable us to treat more patients," said Donald B. Fuller, M.D., radiation oncologist, CyberKnife Centers of San Diego. "The technology also has the potential to facilitate and improve timely communication about a patient's treatment plan among all treating physicians, helping us ensure that patients receive the best possible cancer care."

Unlike previously developed radiation treatment software, Accuray's PlanTouch is specifically designed for use on the iPad. For example, treatment planning displays are designed and formatted specifically for the iPad's smaller screen and can be manipulated using the iPad's touch screen capabilities. In addition, protections are in place to safeguard patients personal and health information and to ensure that physicians are accessing and analyzing the correct treatment plan for each patient.

"At Accuray, we continue to supply our physicians and patients with innovative, cutting-edge treatment solutions," said Euan S. Thomson, Ph.D., president and chief executive officer of Accuray. "The healthcare field is constantly evolving and mobility is more important than ever before. With PlanTouch, we are putting the power of the CyberKnife System's treatment planning technology onto the iPad and into the hands of treating physicians. The result is an application that meets an evolving need in radiation oncology and demonstrates our continued commitment to breaking new ground in the delivery of better, faster and more accurate cancer care."

Users can now purchase a software license upgrade for their CyberKnife Systems and download the app through the Apple® App Store™ to enable PlanTouch.

Please follow this link for a demonstration of PlanTouch.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company's leading edge technologies – the CyberKnife and TomoTherapy Systems – are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date, more than 300,000 patients worldwide have been treated using the Company's technologies and more than 616 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the anticipated benefits of the Company's new PlanTouch software. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to general market acceptance of the new software; the ease of downloading the application; the ongoing popularity of the iPad platform; and other risks detailed from time to time under the heading "Risk Factors" in the Company's report on Form 10-K for fiscal year 2011 filed on September 19, 2011, and in reports on Form 10-Q for the first and second quarters of fiscal 2012

Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.  Accordingly, investors should not place undue reliance on any forward-looking statements.

Available Topic Expert: For information on the listed expert, click appropriate link.

Euan Thomson, Ph.D.

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=81869

SOURCE Accuray Incorporated